Literature DB >> 17145160

Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention.

Lars Hellman1.   

Abstract

Atopic allergies have increased during the past 20-30 years in frequency quite dramatically and in many countries have reached almost epidemic proportions. Allergies have thereby become one of the major medical issues of the western world. Immunoglobulin E (IgE) is here a central player. IgE is the Ig class that is present in the lowest concentration in human plasma. IgG is, for example, 10 000 to 1 million times more abundant than IgE. However, despite of its low plasma levels IgE is a very important inducer of inflammation, due to its interaction with high-affinity receptors on mast cell and basophils. IgE has been conserved as a single active gene in all placental mammals studied, and the expression of this gene is under a very stringent control, most likely due to its very potent inflammatory characteristics. IgE expression is being regulated at many levels: by cytokines, switch region length, positive and negatively acting transcription factors and suppressors of cytokine signaling (SOCS). In addition, the plasma half-life differs markedly for IgG and IgE, with 21 and 2.5 days, respectively. This review summarizes the rapid progress in our understanding of the complex network of regulatory mechanisms acting on IgE and also how this new information may help us in our efforts to control IgE-mediated inflammatory conditions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145160     DOI: 10.1016/j.biopha.2006.10.001

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  15 in total

1.  Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production.

Authors:  Nina Kim; Sesquile Ramon; Thomas H Thatcher; Collynn F Woeller; Patricia J Sime; Richard P Phipps
Journal:  Eur J Immunol       Date:  2015-11-02       Impact factor: 5.532

Review 2.  Developments in laboratory diagnostics for isocyanate asthma.

Authors:  Adam V Wisnewski
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-04

3.  Mimotopic peptide immunotherapy for the treatment of multiple sclerosis, an inflammatory autoimmune disease.

Authors:  Emanuel Calenoff
Journal:  Am J Clin Exp Immunol       Date:  2013-10-16

Review 4.  Skin and respiratory chemical allergy: confluence and divergence in a hybrid adverse outcome pathway.

Authors:  Ian Kimber; Alan Poole; David A Basketter
Journal:  Toxicol Res (Camb)       Date:  2018-01-26       Impact factor: 3.524

5.  Our perception of the mast cell from Paul Ehrlich to now.

Authors:  Michael A Beaven
Journal:  Eur J Immunol       Date:  2009-01       Impact factor: 5.532

Review 6.  Tracing the Origins of IgE, Mast Cells, and Allergies by Studies of Wild Animals.

Authors:  Lars Torkel Hellman; Srinivas Akula; Michael Thorpe; Zhirong Fu
Journal:  Front Immunol       Date:  2017-12-19       Impact factor: 7.561

Review 7.  IgE repertoire and immunological memory: compartmental regulation and antibody function.

Authors:  Hannah J Gould; Yu-Chang Bryan Wu
Journal:  Int Immunol       Date:  2018-08-30       Impact factor: 5.071

Review 8.  IgE immunotherapy: a novel concept with promise for the treatment of cancer.

Authors:  Debra H Josephs; James F Spicer; Panagiotis Karagiannis; Hannah J Gould; Sophia N Karagiannis
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

9.  Human cord blood derived immature basophils show dual characteristics, expressing both basophil and eosinophil associated proteins.

Authors:  Jeanette Grundström; Jenny M Reimer; Sofia E Magnusson; Gunnar Nilsson; Sara Wernersson; Lars Hellman
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma.

Authors:  Ying Lei; Vamsi Boinapally; Anna Zoltowska; Mikael Adner; Lars Hellman; Gunnar Nilsson
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.